What result is expected with the use of memantine alongside acetylcholinesterase inhibitors in Alzheimer disease?

The use of memantine in combination with acetylcholinesterase inhibitors is expected to lead to delayed disease progression in Alzheimer's disease. Memantine is an NMDA receptor antagonist that works by modulating glutamate activity, which is believed to contribute to neurotoxicity in Alzheimer's patients. Acetylcholinesterase inhibitors, on the other hand, enhance cholinergic transmission by increasing levels of acetylcholine in the brain.

When these two classes of medications are used together, they can have a synergistic effect, potentially leading to better symptom management and slowing the decline in cognitive function. Clinical studies suggest that this combination can provide cognitive benefits and improve overall functioning, making it a common therapeutic strategy in managing Alzheimer's disease.

While completely reversing symptoms or achieving significant improvements in motor functions may not be realistic with these treatments alone, the expectation of a delay in disease progression aligns well with clinical outcomes observed in practice. The combination does not typically lead to a heightened risk of severe nausea, as nausea is not a primary concern with either medication in the context of their combined use for Alzheimer's management.